Cargando…
The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A
BACKGROUND AND AIMS: High lipoprotein(a) [Lp(a)] concentrations are associated with increased coronary artery disease (CAD) risk. Lp(a) is regulated mainly genetically by the LPA gene but involved genetic variants have not been fully elucidated. Improved understanding of the entanglements of genetic...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613586/ https://www.ncbi.nlm.nih.gov/pubmed/35534298 http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.023 |
_version_ | 1783605496959205376 |
---|---|
author | Grüneis, Rebecca Lamina, Claudia Di Maio, Silvia Schönherr, Sebastian Zoescher, Peter Forer, Lukas Streiter, Gertraud Peters, Annette Gieger, Christian Köttgen, Anna Kronenberg, Florian Coassin, Stefan |
author_facet | Grüneis, Rebecca Lamina, Claudia Di Maio, Silvia Schönherr, Sebastian Zoescher, Peter Forer, Lukas Streiter, Gertraud Peters, Annette Gieger, Christian Köttgen, Anna Kronenberg, Florian Coassin, Stefan |
author_sort | Grüneis, Rebecca |
collection | PubMed |
description | BACKGROUND AND AIMS: High lipoprotein(a) [Lp(a)] concentrations are associated with increased coronary artery disease (CAD) risk. Lp(a) is regulated mainly genetically by the LPA gene but involved genetic variants have not been fully elucidated. Improved understanding of the entanglements of genetic Lp(a) regulation may enhance genetic prediction of Lp(a) and CAD risk. We investigated an interaction between the well-known LPA missense SNP rs41272110 (known as Thr3888Pro) and the frequent LPA splicing mutation KIV-2 4925G>A. METHODS: Effects on Lp(a) concentrations were investigated by multiple quantile regression in the German Chronic Kidney Disease (GCKD) study, KORA-F3 and KORA-F4 (n(total) = 10,405) as well as in the UK Biobank (UKB) 200k exome dataset (n = 173,878). The impact of the interaction on CAD risk was assessed by survival analysis in UKB. RESULTS: We observed a significant SNP-SNP interaction in all studies (p = 1.26e-05 to 3.03e-04). In quantile regression analysis, rs41272110 as a predictor shows no impact on Lp(a) (β = −0.06 [-0.79; 0.68], p = 0.879), but in a joint model including both SNPs as predictors, rs41272110 is associated with markedly higher Lp(a) (β = +9.40 mg/dL [6.45; 12.34], p = 4.07e-10). Similarly, rs41272110 shows no effect on CAD in UKB (HR = 1.01 [0.97; 1.04], p = 0.731), while rs41272110 carriers not carrying 4925G>A show an increased CAD risk (HR = 1.10 [1.04; 1.16], p = 6.9e-04). This group corresponds to 4% of the population. Adjustment for apolipoprotein(a) isoforms further modified the effect estimates markedly. CONCLUSIONS: This work emphasizes the complexity of the genetic regulation of Lp(a) and the importance to account for genetic subgroups in Lp(a) association studies and when interpreting genetic cardiovascular risk profiles. |
format | Online Article Text |
id | pubmed-7613586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-76135862022-09-15 The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A Grüneis, Rebecca Lamina, Claudia Di Maio, Silvia Schönherr, Sebastian Zoescher, Peter Forer, Lukas Streiter, Gertraud Peters, Annette Gieger, Christian Köttgen, Anna Kronenberg, Florian Coassin, Stefan Atherosclerosis Article BACKGROUND AND AIMS: High lipoprotein(a) [Lp(a)] concentrations are associated with increased coronary artery disease (CAD) risk. Lp(a) is regulated mainly genetically by the LPA gene but involved genetic variants have not been fully elucidated. Improved understanding of the entanglements of genetic Lp(a) regulation may enhance genetic prediction of Lp(a) and CAD risk. We investigated an interaction between the well-known LPA missense SNP rs41272110 (known as Thr3888Pro) and the frequent LPA splicing mutation KIV-2 4925G>A. METHODS: Effects on Lp(a) concentrations were investigated by multiple quantile regression in the German Chronic Kidney Disease (GCKD) study, KORA-F3 and KORA-F4 (n(total) = 10,405) as well as in the UK Biobank (UKB) 200k exome dataset (n = 173,878). The impact of the interaction on CAD risk was assessed by survival analysis in UKB. RESULTS: We observed a significant SNP-SNP interaction in all studies (p = 1.26e-05 to 3.03e-04). In quantile regression analysis, rs41272110 as a predictor shows no impact on Lp(a) (β = −0.06 [-0.79; 0.68], p = 0.879), but in a joint model including both SNPs as predictors, rs41272110 is associated with markedly higher Lp(a) (β = +9.40 mg/dL [6.45; 12.34], p = 4.07e-10). Similarly, rs41272110 shows no effect on CAD in UKB (HR = 1.01 [0.97; 1.04], p = 0.731), while rs41272110 carriers not carrying 4925G>A show an increased CAD risk (HR = 1.10 [1.04; 1.16], p = 6.9e-04). This group corresponds to 4% of the population. Adjustment for apolipoprotein(a) isoforms further modified the effect estimates markedly. CONCLUSIONS: This work emphasizes the complexity of the genetic regulation of Lp(a) and the importance to account for genetic subgroups in Lp(a) association studies and when interpreting genetic cardiovascular risk profiles. 2022-05-01 2022-04-26 /pmc/articles/PMC7613586/ /pubmed/35534298 http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.023 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Grüneis, Rebecca Lamina, Claudia Di Maio, Silvia Schönherr, Sebastian Zoescher, Peter Forer, Lukas Streiter, Gertraud Peters, Annette Gieger, Christian Köttgen, Anna Kronenberg, Florian Coassin, Stefan The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A |
title | The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A |
title_full | The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A |
title_fullStr | The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A |
title_full_unstemmed | The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A |
title_short | The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A |
title_sort | effect of lpa thr3888pro on lipoprotein(a) and coronary artery disease is modified by the lpa kiv-2 variant 4925g>a |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613586/ https://www.ncbi.nlm.nih.gov/pubmed/35534298 http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.023 |
work_keys_str_mv | AT gruneisrebecca theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT laminaclaudia theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT dimaiosilvia theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT schonherrsebastian theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT zoescherpeter theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT forerlukas theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT streitergertraud theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT petersannette theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT giegerchristian theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT kottgenanna theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT kronenbergflorian theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT coassinstefan theeffectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT gruneisrebecca effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT laminaclaudia effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT dimaiosilvia effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT schonherrsebastian effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT zoescherpeter effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT forerlukas effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT streitergertraud effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT petersannette effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT giegerchristian effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT kottgenanna effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT kronenbergflorian effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga AT coassinstefan effectoflpathr3888proonlipoproteinaandcoronaryarterydiseaseismodifiedbythelpakiv2variant4925ga |